Cargando…

Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell

The potent cytotoxic property of Vγ2Vδ2 T cells makes them attractive for adoptive T cell transfer therapy. The transfusing of the expanded Vγ2Vδ2 T cells into cancer patients shows well-tolerated, but the clinical response rates are required to be improved, implying that there is still an unmet eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Rui, He, Qing, Zhou, Hui, Gong, Cheng, Wang, Xing, Song, Xingpan, Luo, Fang, Lei, Yang, Ni, Qian, Wang, Zili, Xu, Shasha, Xue, Yan, Zhang, Man, Wen, Haimei, Fang, Lijuan, Zeng, Liang, Yan, Yongxiang, Shi, Jian, Zhang, Jing, Yi, Jizu, Zhou, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247338/
https://www.ncbi.nlm.nih.gov/pubmed/35784353
http://dx.doi.org/10.3389/fimmu.2022.923969
_version_ 1784739144139800576
author Yang, Rui
He, Qing
Zhou, Hui
Gong, Cheng
Wang, Xing
Song, Xingpan
Luo, Fang
Lei, Yang
Ni, Qian
Wang, Zili
Xu, Shasha
Xue, Yan
Zhang, Man
Wen, Haimei
Fang, Lijuan
Zeng, Liang
Yan, Yongxiang
Shi, Jian
Zhang, Jing
Yi, Jizu
Zhou, Pengfei
author_facet Yang, Rui
He, Qing
Zhou, Hui
Gong, Cheng
Wang, Xing
Song, Xingpan
Luo, Fang
Lei, Yang
Ni, Qian
Wang, Zili
Xu, Shasha
Xue, Yan
Zhang, Man
Wen, Haimei
Fang, Lijuan
Zeng, Liang
Yan, Yongxiang
Shi, Jian
Zhang, Jing
Yi, Jizu
Zhou, Pengfei
author_sort Yang, Rui
collection PubMed
description The potent cytotoxic property of Vγ2Vδ2 T cells makes them attractive for adoptive T cell transfer therapy. The transfusing of the expanded Vγ2Vδ2 T cells into cancer patients shows well-tolerated, but the clinical response rates are required to be improved, implying that there is still an unmet efficacy with low toxicity for this novel anti-tumor therapy. In this study, we test the anti-tumor efficacy of a Y-body-based bispecific antibody (bsAb) Vγ2 x PD-L1 that preferentially redirects Vγ2Vδ2 T cells to combat PD-L1 positive tumor cells. With nanomolar affinity levels to Vγ2Vδ2 T cells and PD-L1+ tumor cells, Vγ2 x PD-L1 bridges a Vγ2Vδ2 T cell with a SKOV3 tumor cell to form a cell-to-cell conjugation. In a PD-L1-dependent manner, the bsAb elicits effective activation (CD25+CD69+), IFNγ releasing, degranulation (CD107a+), and cytokine production (IFNγ+ and TNFα+) of expanded Vγ2Vδ2 T cells. The activations of the Vγ2Vδ2 T cells eliminate PD-L1-expressing human cancer cell lines, including H1975, SKOV3, A375, H1299, and H2228 cells, but not PD-L1 negative cells including HEK-293 (293) cells and healthy PBMCs. Finally, we show that combining Vγ2 x PD-L1 with adoptively transferring Vγ2Vδ2 T cells inhibits the growth of existing tumor xenografts and increases the number of Vγ2Vδ2 T cells into the tumor bed. Vγ2 x PD-L1 represents a promising reagent for increasing the efficacy of adoptively transferred Vγ2Vδ2 T cells in the treatment of PD-L1 positive malignant tumors.
format Online
Article
Text
id pubmed-9247338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92473382022-07-02 Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell Yang, Rui He, Qing Zhou, Hui Gong, Cheng Wang, Xing Song, Xingpan Luo, Fang Lei, Yang Ni, Qian Wang, Zili Xu, Shasha Xue, Yan Zhang, Man Wen, Haimei Fang, Lijuan Zeng, Liang Yan, Yongxiang Shi, Jian Zhang, Jing Yi, Jizu Zhou, Pengfei Front Immunol Immunology The potent cytotoxic property of Vγ2Vδ2 T cells makes them attractive for adoptive T cell transfer therapy. The transfusing of the expanded Vγ2Vδ2 T cells into cancer patients shows well-tolerated, but the clinical response rates are required to be improved, implying that there is still an unmet efficacy with low toxicity for this novel anti-tumor therapy. In this study, we test the anti-tumor efficacy of a Y-body-based bispecific antibody (bsAb) Vγ2 x PD-L1 that preferentially redirects Vγ2Vδ2 T cells to combat PD-L1 positive tumor cells. With nanomolar affinity levels to Vγ2Vδ2 T cells and PD-L1+ tumor cells, Vγ2 x PD-L1 bridges a Vγ2Vδ2 T cell with a SKOV3 tumor cell to form a cell-to-cell conjugation. In a PD-L1-dependent manner, the bsAb elicits effective activation (CD25+CD69+), IFNγ releasing, degranulation (CD107a+), and cytokine production (IFNγ+ and TNFα+) of expanded Vγ2Vδ2 T cells. The activations of the Vγ2Vδ2 T cells eliminate PD-L1-expressing human cancer cell lines, including H1975, SKOV3, A375, H1299, and H2228 cells, but not PD-L1 negative cells including HEK-293 (293) cells and healthy PBMCs. Finally, we show that combining Vγ2 x PD-L1 with adoptively transferring Vγ2Vδ2 T cells inhibits the growth of existing tumor xenografts and increases the number of Vγ2Vδ2 T cells into the tumor bed. Vγ2 x PD-L1 represents a promising reagent for increasing the efficacy of adoptively transferred Vγ2Vδ2 T cells in the treatment of PD-L1 positive malignant tumors. Frontiers Media S.A. 2022-06-17 /pmc/articles/PMC9247338/ /pubmed/35784353 http://dx.doi.org/10.3389/fimmu.2022.923969 Text en Copyright © 2022 Yang, He, Zhou, Gong, Wang, Song, Luo, Lei, Ni, Wang, Xu, Xue, Zhang, Wen, Fang, Zeng, Yan, Shi, Zhang, Yi and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yang, Rui
He, Qing
Zhou, Hui
Gong, Cheng
Wang, Xing
Song, Xingpan
Luo, Fang
Lei, Yang
Ni, Qian
Wang, Zili
Xu, Shasha
Xue, Yan
Zhang, Man
Wen, Haimei
Fang, Lijuan
Zeng, Liang
Yan, Yongxiang
Shi, Jian
Zhang, Jing
Yi, Jizu
Zhou, Pengfei
Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title_full Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title_fullStr Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title_full_unstemmed Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title_short Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell
title_sort vγ2 x pd-l1, a bispecific antibody targeting both the vγ2 tcr and pd-l1, improves the anti-tumor response of vγ2vδ2 t cell
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247338/
https://www.ncbi.nlm.nih.gov/pubmed/35784353
http://dx.doi.org/10.3389/fimmu.2022.923969
work_keys_str_mv AT yangrui vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT heqing vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT zhouhui vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT gongcheng vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT wangxing vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT songxingpan vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT luofang vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT leiyang vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT niqian vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT wangzili vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT xushasha vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT xueyan vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT zhangman vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT wenhaimei vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT fanglijuan vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT zengliang vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT yanyongxiang vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT shijian vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT zhangjing vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT yijizu vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell
AT zhoupengfei vg2xpdl1abispecificantibodytargetingboththevg2tcrandpdl1improvestheantitumorresponseofvg2vd2tcell